Pharmaceutical composition of alkynyl-substituted quinazoline compound or salt thereof and preparation method thereof
By developing alkynyl-substituted quinazoline compounds and their pharmaceutical compositions, the problem of difficulty in entering the brain metastasis in cancer treatment is solved, effective inhibition of ErbB kinase is achieved, and a stable and easy-to-production treatment plan is provided.
Patent Information
- Application Number
- CN202410612737.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-17
- Filing Date
- 2024-05-16
- Publication Date
- 2024-11-22
AI Technical Summary
Existing cancer treatment methods are difficult to effectively cross the blood-tumor barrier, especially in lung and breast cancers with brain metastases, where there is a problem of difficulty in drug entry, and the development of inhibitors for ErbB kinase activity has not been fully resolved.
An alkynyl-substituted quinazoline compound and its pharmaceutically acceptable salt or solvate were developed to form a stable, easy-to-productive pharmaceutical composition for use as an irreversible ErbB kinase inhibitor, against Diseases involving ErbB kinase activity are treated.
The pharmaceutical composition has high dissolution, good stability, low total impurity content, easy operation, suitable for industrial production and storage, can effectively inhibit the activity of the ErbB family receptor tyrosine kinase, and is used to treat excessive, including cancer, Proliferation disorders.
Smart Images

Figure CN118986989A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of pharmaceutical preparations, and in particular, relates to a composition of an alkynyl-substituted quinazoline compound or a pharmaceutically acceptable salt thereof or a solvate thereof, a pharmaceutical composition and a preparation method thereof. Background Art
[0002] The type I receptor tyrosine kinase family consists of four closely related receptors: ErbB1 (EFGR or HER1), ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4). The receptors are transmembrane glycoproteins containing an extracellular domain for ligand binding and (except for HER3) an intracellular catalytically active tyrosine kinase domain. The receptors transmit extracellular signals to the nucleus via the cytosol via a signal transduction cascade. Extracellular signals are transmitted by ligand binding to dimeric receptors (except for ErbB2, for which a high affinity soluble ligand has yet to be identified). After ligand binding, type I receptor tyrosine kinases homodimerize or heterodimerize with another member of the receptor subfamily (Lemmon MA, Experiment. Cell Res. (2009), 315: 638-648). ErbB2 participates in this process by heterodimerization and is a preferred partner for heterodimerization (Brennan PJ et al., Oncogene (2000), 19: 6093). Dimerization leads to activation of ErbB receptors due to autophosphorylation of the intracellular domain. This autophosphorylation recruits adaptor proteins and leads to a phosphorylation cascade that transmits signals throughout the cell. The type I receptor tyrosine kinase family (ErbB family) conducts signals through the ras / raf / MEK / MAPK pathway and the PI3K / Akt pathway. This signal transduction pathway leads to cell proliferation and cell survival by inhibiting apoptosis.
[0003] In cancer patients, especially lung cancer, breast cancer and melanoma, the incidence of metastasis to the brain is increasing. The brain is considered a "sanctuary" because the blood-tumor barrier limits the ability of drugs to enter and kill tumor cells (Steeg, PS et al., Nat. Rev. Cancer (2011) 11: 352). Brain metastasis from lung cancer accounts for 40%-50% of all brain metastases, and nearly half of the brain metastases from lung cancer have EGFR mutations (Eichler, AF et al., NeuroOncology (2010), 12: 1193). Herceptin is a humanized form of anti-ErbB2 monoclonal antibody approved for breast cancer, colorectal cancer and head and neck cancer. Although the use of Herceptin can significantly improve the outcome of HER2-positive breast cancer patients, many breast cancer patients develop brain metastases while being treated with Herceptin (http: / / www.cityofhope.org / eHope, 11(2) February 21, 2012; Heitz, F et al., Ann. Oncol. (2011) 22: 1571; Bendell, J. et al., Cancer (2003) 97: 2972).
[0004] There is a continuing need for new cancer therapies, particularly in the context of significant medical gaps in compounds that can treat brain tumors. WO2012 / 122058 discloses an alkynyl-substituted quinazoline compound that is an irreversible ErbB kinase inhibitor useful for treating diseases and conditions involving ErbB kinase activity, such as cancer.
[0005] Therefore, it is of great significance to study and prepare suitable pharmaceutical composition forms of alkynyl-substituted quinazoline compounds. Summary of the invention
[0006] The present invention provides a pharmaceutical composition comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein the pharmaceutical composition has the advantages of high solubility, good stability, low total impurity content, simple operation and easy industrial production. The present application also provides a method for preparing the pharmaceutical composition and its application.
[0007]
[0008] The compound represented by formula (I) is (E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(2-(3-oxa-bicyclo[3,1,0]hex-6-yl)ethynyl)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide.
[0009] In one aspect, the present invention provides a pharmaceutical composition comprising a compound represented by formula (I) or a pharmaceutically acceptable salt or a solvate thereof, which further comprises a pharmaceutically acceptable excipient.
[0010] In some embodiments, the present invention provides a pharmaceutical composition comprising a compound represented by formula (I) or a pharmaceutically acceptable salt or a solvate thereof, which further comprises a filler, a binder, a disintegrant, a glidant or a lubricant.
[0011] In some embodiments, the pharmaceutical composition described herein comprises, relative to the total amount of the pharmaceutical composition:
[0012] 5wt%-20wt% of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof;
[0013] 60wt%-90wt% of a filler, wherein the filler is selected from one or more of starch, lactose, microcrystalline cellulose and mannitol, preferably selected from lactose and / or microcrystalline cellulose;
[0014] 0.10wt%-1.00wt% of a binder, wherein the binder is selected from one or more of povidone, polyethylene glycol, hydroxypropyl methylcellulose and gelatin, preferably hydroxypropyl methylcellulose;
[0015] 1.00wt%-5.00wt% of a disintegrant, wherein the disintegrant is selected from one or more of dry starch, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose and cross-linked polyvinyl pyrrolidone, preferably cross-linked polyvinyl pyrrolidone;
[0016] 0.10wt%-1.00wt% of a glidant, wherein the glidant is selected from one or more of micropowdered silica gel, talc, magnesium stearate, sodium stearyl fumarate and silicon dioxide, preferably silicon dioxide and / or magnesium stearate; and
[0017] 0.10wt%-5.00wt% of a lubricant, wherein the lubricant is selected from one or more of micro powder silica gel, talc, hydrogenated vegetable oil, polyethylene glycol and magnesium stearate, preferably magnesium stearate.
[0018] In some embodiments, the pharmaceutical composition described herein comprises:
[0019] (i) a granular mixture of an active agent, wherein the active agent is a compound of formula (I) or a pharmaceutically acceptable salt and / or a solvate thereof; and
[0020] (ii) External capsule.
[0021] The active agent granule mixture comprises the compound of formula (I) or a pharmaceutically acceptable salt and / or a solvate thereof, a part of a disintegrant, a binder and a filler.
[0022] The outer capsule shell contains the remainder of the disintegrant, as well as a glidant and a lubricant.
[0023] Additionally, the particulate mixture of active agent comprises 70%-80%, preferably 72%-78%, most preferably 75% by weight of the disintegrant in the pharmaceutical composition.
[0024] On the other hand, the present application provides a method for preparing the pharmaceutical composition as described above, which comprises mixing an active agent and a filler, a disintegrant and a binder and then granulating the mixture to obtain a granular mixture of the active agent, and then mixing the granular mixture with the remaining amount of the disintegrant, as well as a glidant and a lubricant to obtain the pharmaceutical composition of the present invention.
[0025] In another aspect, the present application provides the use of the above pharmaceutical composition in the preparation of a medicament for treating a disease involving ErbB kinase activity, such as a hyperproliferative disorder (eg, cancer).
[0026] Compared with the prior art, the present invention has the following advantages and excellent technical effects: the preparation method of the present invention is simple, the operation is simple, and it is easy to scale up the production; the pharmaceutical composition of the present invention has good stability, and the growth of related substances is slow, which is conducive to the production and storage of the product. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 Drug concentration in plasma of beagle dogs after oral administration of the raw material drug of the compound represented by formula (I), wherein R drug: raw material drug capsule.
[0028] Figure 2 Drug concentration in plasma of beagle dogs after oral administration of capsules of the compound of formula (I), wherein drug A is a capsule of the compound of formula (I) according to the present invention.
[0029] Figure 3 Comparison of the concentration of the compound of formula (I) in the plasma of beagle dogs after administration of the preparation group / raw drug group, wherein R drug: raw drug capsule; A drug: capsule of the compound of formula (I) according to the present invention. DETAILED DESCRIPTION
[0030] Hereinafter, exemplary embodiments of the present invention are described, but the protection scope of the present invention is not limited thereto.
[0031] Pharmaceutical composition of the present invention
[0032] The present invention provides a pharmaceutical composition comprising a compound represented by formula (I) (hereinafter also referred to as the compound of formula (I)) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
[0033] The present invention provides a pharmaceutical composition comprising a compound represented by formula (I) (hereinafter also referred to as the compound of formula (I)) or a pharmaceutically acceptable salt or a solvate thereof, and a filler, a binder, a disintegrant, a glidant or a lubricant.
[0034]
[0035] The compound of formula (I) (E)-N-(4-(3-chloro-4-fluoroanilino)-7-(2-(3-oxa-bicyclo[3,1,0]hex-6-yl)ethynyl)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide is an irreversible ErbB kinase inhibitor and can be used to treat diseases involving ErbB kinase activity, such as hyperproliferative diseases (e.g., cancer).
[0036] In some embodiments, the pharmaceutical composition is a unit dose pharmaceutical composition. In some embodiments, the mass of the compound of formula (I) or its pharmaceutically acceptable salt or solvate thereof in each unit dose of the composition is 0.5 mg-100 mg. In some embodiments, the mass of the compound of formula (I) in each unit dose of the composition is 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, 94mg, 95mg, 96mg, 97mg, 98mg, 99mg or 100mg; or a range consisting of any of the foregoing values as endpoints. In some embodiments, the mass of the compound of formula (I) in each unit dose of the composition is 0.5 mg-100 mg, 1 mg-50 mg, 1 mg-30 mg, 2 mg-30 mg, 2 mg-10 mg, 5 mg-10 mg, or 5 mg-30 mg.
[0037] In some embodiments, the amount of the compound of formula (I) or its pharmaceutically acceptable salt or its solvate in the pharmaceutical composition of the present invention is selected from 5wt%-20wt%. In some embodiments, in the pharmaceutical composition of the present invention, the amount of the compound of formula (I) or its pharmaceutically acceptable salt or its solvate is selected from 5wt%, 6wt%, 7wt%, 8w%, 9wt%, 10wt%, 11wt%, 12wt%, 13wt%, 14wt%, 15wt%, 16wt%, 17wt%, 18wt%, 19wt%, or 20wt%; or any of the aforementioned values as the range of endpoints. In some embodiments, in the pharmaceutical composition of the present invention, the amount of the compound of formula (I) or its pharmaceutically acceptable salt or its solvate is selected from about 5wt%-15wt%, preferably about 10wt%.
[0038] In some embodiments, the filler is selected from one or more of starch, lactose, microcrystalline cellulose and mannitol. In some embodiments, the filler is selected from lactose and / or microcrystalline cellulose.
[0039] In some embodiments, the amount of the filler in the pharmaceutical composition according to the present invention is selected from 60wt%-90wt%. In some embodiments, in the pharmaceutical composition of the present invention, the amount of the filler is selected from about 60wt%, 61wt%, 62wt%, 63wt%, 64wt%, 65wt%, 66wt%, 67wt%, 68wt%, 69wt%, 70wt%, 71wt%, 72wt%, 73wt%, 74wt%, 75wt%, 76wt%, 77wt%, 78wt%, 79wt%, 80wt%, 81wt%, 82wt%, 83wt%, 84wt%, 85wt%, 86wt%, 87wt%, 88wt%, 89wt%, 90wt%; or any of the aforementioned values as the range consisting of endpoints. In some embodiments, in the pharmaceutical composition of the present invention, the amount of the filler is selected from about 75 wt%-90 wt%, preferably about 80 wt%-90 wt%, more preferably about 85 wt%.
[0040] In a preferred embodiment, the filler is a mixture of two or more fillers. For example, the mixture of fillers comprises at least two of starch, lactose, microcrystalline cellulose and mannitol. Preferably, the filler is a mixture of lactose and microcrystalline cellulose. For example, the mass ratio of lactose: microcrystalline cellulose can be selected from: 5:1 to 1:5, preferably 3:1 to 1:3, for example, 3:1, 2.8:1, 2.5:1, 2.4:1, 2.1:1, 2:1, 1.9:1, 1.8:1, 1.7:1, 1.6:1, 1.5:1, 1.4:1, 1.3:1, 1.2:1, 1.1:1, 1:1, 1:1.5, 1:2, 1:2.5 or 1:3.
[0041] In some embodiments, the binder is selected from one or more of povidone, polyethylene glycol, hydroxypropyl methylcellulose and gelatin. In some embodiments, the binder is hydroxypropyl methylcellulose.
[0042] In some embodiments, the amount of the binder in the pharmaceutical composition according to the present invention is selected from 0.10wt%-1.00wt%. In some embodiments, in the pharmaceutical composition of the present invention, the amount of the binder is selected from 0.10wt%, 0.20wt%, 0.30wt%, 0.40wt%, 0.50wt%, 0.60wt%, 0.70wt%, 0.80wt%, 0.90wt%, 1.00wt%; or any of the aforementioned values as the range of endpoints. In some embodiments, in the pharmaceutical composition of the present invention, the amount of the binder is selected from 0.30wt%-0.80wt%, preferably 0.30wt%-0.50wt%, more preferably about 0.40wt%.
[0043] In some embodiments, the disintegrant is selected from one or more of dry starch, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose and cross-linked polyvinyl pyrrolidone. In some embodiments, the disintegrant is cross-linked polyvinyl pyrrolidone.
[0044] In some embodiments, the amount of the disintegrant in the pharmaceutical composition according to the present invention is selected from 1.00wt%-5.00wt%. In some embodiments, in the pharmaceutical composition of the present invention, the amount of the disintegrant is selected from 1.00wt%, 1.10wt%, 1.20wt%, 1.30wt%, 1.40wt%, 1.50wt%, 1.60wt%, 1.70wt%, 1.80wt%, 1.90wt%, 2.00wt%, 2.05wt%, 2.10wt%, 2.15wt%, 2.20wt%, 2.25wt%, 2.30wt%, 2.35wt%, 2.40wt%, 2.45wt%. %, 2.50wt%, 2.55wt%, 2.60wt%, 2.65wt%, 2.70wt%, 2.75wt%, 2.80wt%, 2.85wt%, 2.90wt%, 2.95wt%, 3.00wt%, 3.20wt%, 3.40wt%, 3.60wt%, 3.80wt%, 4.00wt%, 4.20wt%, 4.40wt%, 4.60wt%, 4.80wt%, or 5.00wt%; or a range consisting of any of the foregoing values as endpoints. In some embodiments, in the pharmaceutical composition of the present invention, in the pharmaceutical composition of the present invention, the amount of the disintegrant is selected from 2.00wt%-4.00wt%, preferably 2.50wt%-3.00wt%, more preferably about 2.65wt%, 2.66wt%, 2.67wt%, 2.68wt%, 2.69wt%.
[0045] In some embodiments, the glidant is selected from one or more of micro powder silica gel, talc, magnesium stearate, sodium stearyl fumarate and silicon dioxide. In some embodiments, the glidant is silicon dioxide and / or magnesium stearate.
[0046] In some embodiments, the amount of the glidant in the pharmaceutical composition according to the present invention is selected from 0.10wt%-1.00wt%. In some embodiments, in the pharmaceutical composition of the present invention, the amount of the glidant is selected from 0.10wt%, 0.15wt%, 0.20wt%, 0.25wt%, 0.30wt%, 0.35wt%, 0.40wt%, 0.45wt%, 0.50wt%, 0.55wt%, 0.60wt%, 0.65wt%, 0.70wt%, 0.75wt%, 0.80wt%, 0.85wt%, 0.90wt%, 0.95wt%, or 1.00wt%; or any of the foregoing values as the range of endpoints. In some embodiments, in the pharmaceutical composition of the present invention, the amount of the glidant is selected from 0.50wt%-0.80wt%, preferably 0.60wt%-0.75wt%, more preferably 0.65wt%, 0.66wt%, 0.67wt%, 0.68wt%, 0.69wt%.
[0047] In some embodiments, the lubricant is selected from one or more of micro powder silica gel, talc, hydrogenated vegetable oil, polyethylene glycol and magnesium stearate. In some embodiments, the lubricant is magnesium stearate.
[0048] In some embodiments, the amount of the lubricant in the pharmaceutical composition according to the present invention is selected from 0.10wt%-5.00wt%. In some embodiments, in the pharmaceutical composition of the present invention, the amount of the lubricant is selected from 0.10wt%, 0.15wt%, 0.20wt%, 0.25wt%, 0.30wt%, 0.35wt%, 0.40wt%, 0.45wt%, 0.50wt%, 0.55wt%, 0.60wt%, 0.65wt%, 0.70wt%, 0.75wt%, 0.80wt%, 0.85wt%, 0.90wt%, 0.95wt%, 1.00wt%, 1.10wt%, 1.20wt%, 1.30wt%, 1.40wt%, 1.50wt%. %, 1.60wt%, 1.70wt%, 1.80wt%, 1.90wt%, 2.00wt%, 2.10wt%, 2.20wt%, 2.30wt%, 2.40wt%, 2.50wt%, 2.60wt%, 2.70wt%, 2.80wt%, 2.90wt%, 3.00wt%, 3.20wt%, 3.40wt%, 3.60wt%, 3.80wt%, 4.00wt%, 4.20wt%, 4.40wt%, 4.60wt%, 4.80wt%, or 5.00wt%; or any of the foregoing values as endpoints. In some embodiments, in the pharmaceutical composition of the present invention, the amount of the lubricant is selected from 0.50wt%-2.50wt%, preferably 0.70wt%-1.50wt%, more preferably 1.00wt%.
[0049] The present application provides a solid pharmaceutical composition, which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt or a solvate thereof, and a filler, a binder, a disintegrant, a glidant or a lubricant.
[0050] In some embodiments, the dosage form of the pharmaceutical composition can be selected from tablets, capsules, powders, granules, pills, pellets, pastes, dispersions or inhalable powders, preferably capsules or tablets.
[0051] In some embodiments of the present application, a pharmaceutical composition is provided, which contains:
[0052] (i) a granular mixture of an active agent, wherein the active agent is a compound of formula (I) or a pharmaceutically acceptable salt and / or a solvate thereof; and
[0053] (ii) External capsule.
[0054] In some embodiments, the active agent granule mixture comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof and / or a solvate thereof, a portion of a disintegrant, a binder, and a filler. In some embodiments, the outer capsule shell comprises the remainder of the disintegrant, as well as a glidant and a lubricant.
[0055] In a preferred embodiment, the particulate mixture of active agent comprises 70%-80%, preferably 72%-78%, most preferably 75% by weight of the disintegrant in the pharmaceutical composition.
[0056] In some embodiments, the pharmaceutical composition is a preparation suitable for oral administration, including tablets, capsules, powders, granules, pills, micropills, pastes, dispersions or inhalable powders, etc., preferably tablets and capsules.
[0057] In some embodiments, the pharmaceutical composition is formulated into a pharmaceutical composition in unit dose form. In some embodiments, the pharmaceutical composition in unit dose form contains 0.5mg-100mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof. In some embodiments, the pharmaceutical composition in unit dose form contains 0.5mg-100mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof. In some embodiments, the pharmaceutical composition in unit dose form contains 1mg-50mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof. In some embodiments, the pharmaceutical composition in unit dose form contains 1mg-30mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof. In some embodiments, the pharmaceutical composition in unit dose form contains 2mg-30mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof, preferably 2mg-10mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof, more preferably 5mg-30mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof. In some specific embodiments, the pharmaceutical composition in unit dose form contains 1 mg, 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
[0058] In some specific embodiments, the pharmaceutical composition in the form of a unit dose is a capsule containing 1 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof. In some specific embodiments, the pharmaceutical composition in the form of a unit dose is a capsule containing 2 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof. In some specific embodiments, the pharmaceutical composition in the form of a unit dose is a capsule containing 5 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof. In some specific embodiments, the pharmaceutical composition in the form of a unit dose is a capsule containing 10 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof. In some specific embodiments, the pharmaceutical composition in the form of a unit dose is a capsule containing 30 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof.
[0059] In some embodiments, the pharmaceutical composition is a capsule, including a soft capsule and a hard capsule, wherein the capsule shell can be a hydroxypropyl methylcellulose capsule or a gelatin capsule.
[0060] Those skilled in the art should also understand that, in addition to the active ingredient compound of formula (I) and fillers, binders, disintegrants, glidants or lubricants described above, the pharmaceutical composition of the present application may also include other pharmaceutically acceptable excipients or adjuvants as needed, such as but not limited to antioxidants, preservatives, colorants, flavoring agents, etc., the selection and amount of which can be adjusted by those skilled in the art according to actual needs.
[0061] The pharmaceutical composition of the present application has high purity (i.e., low impurity content). In some embodiments, the total impurity content of the pharmaceutical composition of the present application is 0.7% or less, preferably 0.65% or less, more preferably 0.64% or less, particularly preferably 0.60% or less, 0.58% or less, 0.55% or less, 0.52% or less, 0.50% or less, 0.45% or less, 0.44% or less, etc.
[0062] In the completed 3-month stability test, the results showed that the impurities of the pharmaceutical composition according to the present application changed after being placed under the conditions of accelerated test 1 (40°C ± 2°C, RH75% ± 5%) for 3 months; under the conditions of accelerated test 2 (25°C ± 2°C, RH60% ± 5%) and long-term test (5°C ± 3°C), there were no significant changes in various tests, all of which met the regulations. Therefore, the pharmaceutical composition according to the present application can ensure that the compound represented by formula (I) maintains good stability within the expected validity period. In addition, the pharmaceutical composition described in the present application has obvious advantages in terms of solubility and impurities.
[0063] Implementation Methods of the Application
[0064] In some embodiments of the present application, the pharmaceutical composition described in the present application comprises, relative to the total amount of the pharmaceutical composition:
[0065] 5wt%-20wt% of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof;
[0066] 60wt%-90wt% of a filler, wherein the filler is selected from one or more of starch, lactose, microcrystalline cellulose and mannitol, preferably selected from lactose and / or microcrystalline cellulose;
[0067] 0.10wt%-1.00wt% of a binder, wherein the binder is selected from one or more of povidone, polyethylene glycol, hydroxypropyl methylcellulose and gelatin, preferably hydroxypropyl methylcellulose;
[0068] 1.00wt%-5.00wt% of a disintegrant, wherein the disintegrant is selected from one or more of dry starch, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose and cross-linked polyvinyl pyrrolidone, preferably cross-linked polyvinyl pyrrolidone;
[0069] 0.10wt%-1.00wt% of a glidant, wherein the glidant is selected from one or more of micropowdered silica gel, talc, magnesium stearate, sodium stearyl fumarate and silicon dioxide, preferably silicon dioxide and / or magnesium stearate; and
[0070] 0.10wt%-5.00wt% of a lubricant, wherein the lubricant is selected from one or more of micro powder silica gel, talc, hydrogenated vegetable oil, polyethylene glycol and magnesium stearate, preferably magnesium stearate.
[0071] In some embodiments of the present application, the pharmaceutical composition described in the present application comprises, relative to the total amount of the pharmaceutical composition:
[0072] 5wt%-20wt% of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof;
[0073] 60wt%-90wt% of a filler, wherein the filler is selected from lactose and microcrystalline cellulose;
[0074] 0.10wt%-1.00wt% of a binder, wherein the binder is hydroxypropyl methylcellulose;
[0075] 1.00wt%-5.00wt% of a disintegrant, wherein the disintegrant is cross-linked polyvinylpyrrolidone;
[0076] 0.10wt%-1.00wt% of a glidant, wherein the glidant is selected from silicon dioxide and / or magnesium stearate; and
[0077] 0.10wt%-5.00wt% of a lubricant, wherein the lubricant is magnesium stearate.
[0078] In some embodiments of the present application, the pharmaceutical composition described in the present application comprises, relative to the total amount of the pharmaceutical composition:
[0079] 5wt%-15wt% of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof;
[0080] 80wt%-90wt% of a filler, wherein the filler is selected from lactose and microcrystalline cellulose;
[0081] 0.30wt%-0.50wt% of a binder, wherein the binder is hydroxypropyl methylcellulose;
[0082] 2.50wt%-3.00wt% of a disintegrant, wherein the disintegrant is cross-linked polyvinylpyrrolidone;
[0083] 0.60wt%-0.75wt% of a glidant, wherein the glidant is selected from silicon dioxide and / or magnesium stearate; and
[0084] 0.70wt%-1.50wt% of a lubricant, wherein the lubricant is magnesium stearate.
[0085] In some embodiments of the present application, the pharmaceutical composition described in the present application comprises, relative to the total amount of the pharmaceutical composition:
[0086] 5wt%-15wt%, preferably about 10wt% of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof;
[0087] 80 wt% to 90 wt%, preferably about 85 wt% of a filler selected from lactose and microcrystalline cellulose;
[0088] 0.30wt%-0.50wt%, preferably about 0.40wt% of a binder, wherein the binder is hydroxypropyl methylcellulose;
[0089] 2.65wt%, 2.66wt%, 2.67wt%, 2.68wt% or 2.69wt% of a disintegrant, wherein the disintegrant is cross-linked polyvinylpyrrolidone;
[0090] 0.65 wt%, 0.66 wt%, 0.67 wt%, 0.68 wt% or 0.69 wt% of a glidant selected from silicon dioxide and / or magnesium stearate; and
[0091] 0.70wt%-1.50wt%, preferably 1.00wt% of a lubricant, wherein the lubricant is magnesium stearate.
[0092] In some embodiments of the present application, the pharmaceutical composition described above is a unit dosage form, such as a tablet or capsule. Preferably, the unit dosage form contains 1 mg, 2 mg, 5 mg, 10 mg, 15 mg, 25 mg, or 30 mg of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
[0093] In some embodiments of the present application, the pharmaceutical composition described in the present application comprises:
[0094] (i) a granular mixture of an active agent, wherein the active agent is a compound of formula (I) or a pharmaceutically acceptable salt and / or a solvate thereof; and
[0095] (ii) the outer capsule,
[0096] The active agent particle mixture comprises a compound of formula (I) or a pharmaceutically acceptable salt and / or a solvate thereof, a portion of a disintegrant, a binder and a filler,
[0097] The outer capsule shell contains the remainder of the disintegrant, as well as a glidant and a lubricant,
[0098] Also, the granular mixture of the active agent comprises 70%-80%, preferably 72%-78%, most preferably 75% by weight of the disintegrant in the pharmaceutical composition.
[0099] In some embodiments, the pharmaceutical composition contains 0.5-3% water based on the total weight of the pharmaceutical composition.
[0100] Preparation method
[0101] In another aspect, the present invention provides a process for preparing a pharmaceutical composition according to the present invention.
[0102] In some embodiments, the present application provides a method for preparing the pharmaceutical composition as described above, which comprises mixing an active agent and a filler, a disintegrant and a binder and then granulating the mixture to obtain a granular mixture of the active agent, and then mixing the granular mixture with the remaining amount of the disintegrant, as well as a glidant and a lubricant to obtain the pharmaceutical composition of the present invention.
[0103] In some embodiments, the granulation described herein can be performed using a wet granulation method.
[0104] In some embodiments, the granular mixture of the active agent is prepared by: mixing a powdered compound of formula (I) or a pharmaceutically acceptable salt thereof / or a solvate thereof with a filler and a disintegrant; adding an aqueous solution of a binder thereto, and then granulating to obtain a granular mixture of the active agent.
[0105] In some preferred embodiments, the aqueous solution of the binder is an aqueous solution, preferably an aqueous solution of 1 wt% to 5 wt% of the binder, more preferably an aqueous solution of 2 wt% of the binder.
[0106] In some embodiments, the compound (I) or its pharmaceutically acceptable salt / or its solvate, filler and disintegrant are mixed in sequence or simultaneously. For example, the compound (I) or its pharmaceutically acceptable salt / or its solvate is mixed evenly with the filler and then mixed with the disintegrant.
[0107] In some embodiments, it is preferred that after granulation, a granule screening step is included.
[0108] In some embodiments, in the mixing operation of the method of the present invention, the mixing time is 1-20 min, preferably 2 min, 3 min, 5 min, 10 min, etc.
[0109] In some embodiments, the sieve for sieving the whole particles is 10-30 mesh, preferably 18 mesh.
[0110] In some embodiments, the sieve used in the granulation process has a mesh size of 10-30, preferably 20 mesh.
[0111] In some embodiments, the granule mixture is mixed with the remaining amount of disintegrant, as well as glidant and lubricant to obtain the outer capsule shell.
[0112] If necessary, fill into capsule shells to prepare capsules.
[0113] The capsule is a hard capsule or a soft capsule, preferably a hard capsule.
[0114] In some embodiments, the capsule shell is a gelatin capsule shell or a plant capsule shell; in some embodiments, the capsule shell is a capsule shell containing hydroxypropyl methylcellulose.
[0115] In some embodiments, the obtained pharmaceutical composition or granule mixture is filled into a capsule shell, and the capsule may be a vegetable capsule. In some embodiments, the capsule is a hydroxypropyl methylcellulose capsule. In some embodiments, the capsule is a gelatin capsule. In some embodiments, each capsule contains 1 mg, 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
[0116] In some embodiments, the method of preparing a pharmaceutical composition of a compound of formula (I) of the present invention comprises:
[0117] 1. Mixing raw materials and auxiliary materials: first mix the filler, the compound of formula (I) or its pharmaceutically acceptable salt or solvate thereof for 2-10 minutes, preferably 5 minutes, then add 60wt%-90wt%, preferably 75wt% of the disintegrant, and mix for 1-5 minutes, preferably 3 minutes;
[0118] 2. Granulation: Add 1wt%-10wt%, preferably 2wt% of an aqueous solution of a binder to the mixed raw materials to prepare a soft material, sieve through a 10-30 mesh, preferably a 20 mesh screen to granulate, and place in an oven to dry the moisture to 1wt%-3wt%; after drying, sieve through a 10-30 mesh, preferably a 18 mesh screen to size the particles;
[0119] 3. Total mixing: add the remaining amount of disintegrant, glidant and lubricant to the granules obtained in step 2 and mix for 1-5 minutes, preferably 3 minutes;
[0120] 4. Fill the granules into capsule shells or perform tablet compression.
[0121] In some embodiments, the method of preparing a pharmaceutical composition of a compound of formula (I) of the present invention comprises:
[0122] 1) Mixing raw materials and auxiliary materials: Mix the compound of formula (I) or its pharmaceutically acceptable salt or solvate with the filler for 5 minutes, then add 75 wt% of the disintegrant and mix for 3 minutes to obtain mixed raw materials and auxiliary materials;
[0123] 2) Granulation: Add 2 wt% of an aqueous solution of a binder to the mixed raw and auxiliary materials obtained in 1) to prepare a soft material, granulate through a 20-mesh sieve, and dry in an oven at 40° C. until the moisture content is 1 wt%-3 wt%; after drying, granulate through an 18-mesh sieve;
[0124] 3) Total mixing: add the remaining amount of disintegrant, glidant and lubricant to the granules obtained in 2) and mix for 3 minutes.
[0125] The selection and dosage of the compound of formula (I) or a pharmaceutically acceptable salt thereof and the filler, binder, disintegrant, glidant or lubricant used in the method are as described above.
[0126] In some embodiments, the solid pharmaceutical composition may further include a coating agent.
[0127] Treatment or prevention methods and uses
[0128] The present application provides the use of the above pharmaceutical composition in the preparation of a medicament for treating a disease involving ErbB kinase activity, such as a hyperproliferative disorder (eg, cancer).
[0129] The pharmaceutical composition provided herein inhibits the activity of ErbB family receptor tyrosine kinases. Therefore, a method for treating a disease or medical condition mediated by type I receptor tyrosine kinases is provided, which comprises administering an effective amount of the pharmaceutical composition to an individual (e.g., a mammal) in need. The type I receptor tyrosine kinase-mediated condition that can be treated according to the method of the invention includes an overproliferation disorder, such as head and neck cancer, lung cancer, breast cancer, colon cancer, ovarian cancer, bladder cancer, gastric cancer, kidney cancer, skin cancer, pancreatic cancer, blood cancer (e.g., leukemia and lymphoma), esophageal cancer, uterine cancer or prostate cancer and other types of overproliferation disorders. In some embodiments, cancer is head and neck cancer, lung cancer (e.g., NSCLC), breast cancer, colon cancer, ovarian cancer, bladder cancer, gastric cancer, kidney cancer, skin cancer, pancreatic cancer, leukemia, lymphoma, esophageal cancer, uterine cancer or prostate cancer. In some embodiments, cancer is breast cancer, gastric cancer or lung cancer. In some embodiments, erlotinib-resistant cancers, such as erlotinib-resistant lung cancer (eg, erlotinib-resistant non-small cell lung cancer) are treated using the compounds of the invention. In some embodiments, the individual has been diagnosed with a hyperproliferative disorder (such as a cancer as described in detail herein).
[0130] The therapeutically effective amount of the pharmaceutical composition of the present invention can be used to treat diseases mediated by regulating or modulating ErbB family kinases. "Effective amount" means the amount of a compound sufficient to achieve treatment of a disease mediated by the activity of one or more ErbB family kinases when administered to a mammal in need of the treatment. Therefore, for example, the therapeutically effective amount of the pharmaceutical composition of the present invention is sufficient to regulate, control or inhibit the activity of one or more ErbB family kinases so that the disease condition mediated by the activity is alleviated or relieved. In the case of cancer or tumors, an effective amount of the drug may have the effect of reducing the number of cancer cells, reducing tumor size, inhibiting (i.e., slowing down and preferably preventing) cancer cells from penetrating into peripheral organs, inhibiting (i.e., slowing down and preferably preventing) tumor metastasis, inhibiting tumor growth to a certain extent, and / or alleviating one or more symptoms associated with the disease to a certain extent. The effective dose can be administered one or more times. For the purposes of the present invention, the effective dose of the pharmaceutical composition of the present invention is an amount sufficient to directly or indirectly achieve preventive or therapeutic treatment.
[0131] The amount of a given drug that will correspond to this amount will vary depending on factors such as the specific compound, the disease state and its severity, the characteristics (e.g., body weight) of the mammal in need of treatment, but remains routinely determinable by one skilled in the art.
[0132] The pharmaceutical compositions of the present invention are administered to mammals alone or in combination to treat hyperproliferative diseases, such as various types of cancer, e.g., colon cancer, ovarian cancer, bladder cancer, stomach cancer, lung cancer, uterine cancer, and prostate cancer. A skilled practitioner can select the appropriate route and dosage to treat the specific hyperproliferative disease to be treated.
[0133] Beneficial Effects
[0134] Compared with the prior art, the present invention has the following advantages and excellent technical effects: the preparation method of the present invention is simple, the operation is simple, and it is easy to scale up the production; the pharmaceutical composition of the present invention has good stability, the growth of related substances is slow, and the total impurity content is low, which is conducive to the production and storage of the product.
[0135] For the purposes of this application, unless otherwise stated, the following terms used in the specification and claims shall have the following meanings.
[0136] Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.
[0137] Unless specifically defined otherwise, ratios (including percentages) or parts used herein are by weight.
[0138] The term "about" should be understood to include within three standard deviations of the mean or within the standard tolerance range in a particular field. In certain embodiments, about should be understood to mean a variation of no more than 0.5. "About" modifies all values listed thereafter. For example, "about 1, 2, 3" means "about 1", "about 2", "about 3". The term "about" used in conjunction with a percentage can mean ± 1%.
[0139] The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit / risk ratio.
[0140] Herein, when referring to the compound of formula (I) or its pharmaceutically acceptable salt or solvate, the amount is calculated based on the compound of formula (I).
[0141] The compound of formula (I) can be administered in its free base form, or in the form of its salt, solvate and prodrug, which is converted into the free base form of the compound of formula (I) in vivo. For example, pharmaceutically acceptable salts of the compound of formula (I) are within the scope of this application, and the salts can be produced from different organic acids and inorganic acids according to methods known in the art.
[0142] In some embodiments, the pharmaceutically acceptable salt of the compound of formula (I) of the present application refers to the salt formed by the compound of formula (I) and a pharmaceutically acceptable acid, wherein the pharmaceutically acceptable acid is selected from sulfuric acid, carbonic acid, nitric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, metaphosphoric acid, trifluoroacetic acid, lactic acid, mandelic acid, glycolic acid, p-toluenesulfonic acid, o-toluenesulfonic acid, citric acid, methanesulfonic acid, formic acid, acetic acid, benzoic acid, phenylacetic acid, malonic acid, cinnamic acid, malic acid, maleic acid, tartaric acid, oxalic acid, fumaric acid, acrylic acid, crotonic acid, oleic acid and linoleic acid. In some embodiments, wherein the pharmaceutically acceptable acid is selected from pharmaceutically acceptable acid selected from sulfuric acid, hydrochloric acid, phosphoric acid, p-toluenesulfonic acid, citric acid, methanesulfonic acid, malic acid, maleic acid, tartaric acid and fumaric acid. In some embodiments, the molar ratio of the compound of Formula I to the pharmaceutically acceptable acid in the salt is 1:0.5, 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5 or 1:4.
[0143] In the present application, the solvate of the compound of formula (I) includes hydrates, such as monohydrate.
[0144] "Unit dosage" or "unit dose" refers to a pharmaceutical composition packaged in a single package for the convenience of taking, for example, "a pharmaceutical composition in unit dosage form" means each capsule. "A pharmaceutical composition in unit dosage form contains 10 mg of a compound of formula (I)" means that each capsule finally prepared contains 10 mg of a compound of formula (I).
[0145] "Patient" or "subject" refers to a mammal, preferably a human.
[0146] "Therapeutically effective amount" means the amount of a compound that, when administered to a human for treating a disease, is sufficient to effect treatment for the disease.
[0147] "Treatment" means any administration of a therapeutically effective amount of a compound, and includes:
[0148] (1) inhibiting a disease in a human being who is experiencing or displaying the pathology or symptomology of the disease (i.e., arresting further development of the pathology and / or symptomology), or
[0149] (2) Ameliorating a disease in a human being experiencing or displaying the pathology or symptomology of the disease (i.e., reversing the pathology and / or symptomology).
[0150] Example
[0151] The following is a further exemplary description of the present invention in conjunction with specific embodiments, but it does not constitute any limitation to the scope of the present invention. The auxiliary materials and reagents used are all commercially available products. The instruments and equipment used can be commonly used instruments and equipment in the art.
[0152] Preparation Example 1 Preparation method of the compound represented by formula (I)
[0153] The compound of formula I was prepared according to Example 4 disclosed in CN103998040.
[0154] In the following examples of the present application, the compound of formula I contains 1 crystal water.
[0155] Example 1: Pharmaceutical composition 1
[0156] Table 1 Component dosage of pharmaceutical composition 1
[0157]
[0158]
[0159] Preparation method:
[0160] 1. Mixing raw materials and auxiliary materials: first mix the filler and the raw material (i.e., the compound of formula (I) obtained in Preparation Example 1) for 5 minutes, then add 75 wt% of the disintegrant in the formula in Table 1 and mix for 3 minutes;
[0161] 2. Granulation: Add 2wt% binder aqueous solution to the mixed raw materials to make a soft material, pass through a 20-mesh sieve to granulate, and place in an oven (40°C) to dry the moisture to 1wt%-3wt%; after drying, use an 18-mesh sieve to granulate;
[0162] 3. Total mixing: Add the remaining amount of disintegrant, glidant and lubricant in the formula of Table 1 to the granules obtained in step 2 and mix for 3 minutes;
[0163] 4. Fill the granules into the capsule shell, wherein the capsule uses No. 1 gelatin capsule shell (Jiujiang Angtai Capsule Co., Ltd., F2112041).
[0164] Example 2: Pharmaceutical composition 2
[0165] Table 2 Ingredient dosage of pharmaceutical composition 2
[0166] Element Dosage (mg / capsule) Compound of formula (I) 15 lactose 165 Microcrystalline Cellulose 90 Hydroxypropyl methylcellulose 1.2 Crospovidone 8 Silicon dioxide 2 Magnesium Stearate 3
[0167] Preparation method:
[0168] 1. Mixing raw materials and auxiliary materials: first mix the filler and the raw material (i.e., the compound of formula (I) obtained in Preparation Example 1) for 5 minutes, then add 75 wt% of the disintegrant in the formula in Table 2 and mix for 3 minutes;
[0169] 2. Granulation: Add 2wt% binder aqueous solution to the mixed raw materials to make a soft material, pass through a 20-mesh sieve to granulate, and place in an oven (40°C) to dry the moisture to 1wt%-3wt%; after drying, use an 18-mesh sieve to granulate;
[0170] 3. Total mixing: Add the remaining amount of disintegrant, glidant and lubricant in the formula of Table 2 to the granules obtained in step 2 and mix for 3 minutes;
[0171] 4. Fill the granules into the capsule shell, wherein the capsule uses No. 1 gelatin capsule shell (Jiujiang Angtai Capsule Co., Ltd., F2112041).
[0172] Example 3: Pharmaceutical composition 3
[0173] Table 3 Ingredient dosage of pharmaceutical composition 3
[0174] Element Dosage (mg / capsule) Compound of formula (I) 60 lactose 165 Microcrystalline Cellulose 90 Hydroxypropyl methylcellulose 1.2 Crospovidone 8 Silicon dioxide 2 Magnesium Stearate 3
[0175] Preparation method:
[0176] 1. Mixing raw materials and auxiliary materials: first mix the filler and the raw material (i.e., the compound of formula (I) obtained in Preparation Example 1) for 5 minutes, then add 75 wt% of the disintegrant in the formula in Table 3 and mix for 3 minutes;
[0177] 2. Granulation: Add 2wt% binder aqueous solution to the mixed raw materials to make a soft material, pass through a 20-mesh sieve to granulate, and place in an oven (40°C) to dry the moisture to 1wt%-3wt%; after drying, use an 18-mesh sieve to granulate;
[0178] 3. Total mixing: Add the remaining amount of disintegrant, glidant and lubricant in the formula of Table 3 to the granules obtained in step 2 and mix for 3 minutes;
[0179] 4. Fill the granules into the capsule shell, wherein the capsule uses No. 1 gelatin capsule shell (Jiujiang Angtai Capsule Co., Ltd., F2112041).
[0180] Example 4: Comparative pharmaceutical composition 1
[0181] Table 4 Comparative dosage of ingredients in pharmaceutical composition 1
[0182] Element Dosage (mg / capsule) Compound of formula (I) 30 lactose 120 Microcrystalline Cellulose 85 Hydroxypropyl methylcellulose 5 Crospovidone 30 Silicon dioxide 15 Magnesium Stearate 15
[0183] Preparation method: Prepare according to the method described in Example 1.
[0184] Test Example 1: Stability test of the composition
[0185] According to the General Chapter 9001 "Guidelines for Stability Testing of APIs and Preparations" of the 2020 edition of the Chinese Pharmacopoeia, the "Technical Guidelines for Stability Studies of Chemical Drugs" issued by the Center for Drug Evaluation of the State Food and Drug Administration, and the requirements of ICH Q1, one batch of preparations was used for influencing factor testing, and two batches of preparations were used for accelerated and long-term testing to examine and determine the storage conditions, packaging materials and shelf life of the products. The details are as follows:
[0186] Influencing factors-high humidity test
[0187] Take the sample of Example 1, and carry out impurity determination and dissolution test at 0 day, 5 day, 10 day and 30 day under high humidity conditions of 25°C and 92.5%RH. The determination results are as follows:
[0188] Table 5 Experimental results of capsules (25°C / 92.5%RH) in Example 1
[0189]
[0190]
[0191] Influencing factors-light test
[0192] 30 mg of the sample of Example 1 was taken and the impurity determination and dissolution test were carried out under light conditions for 0 days and 5 days, 10 days and 30 days. The results are as follows:
[0193] Table 6 Results of the light stability test of capsules in Example 1 (Specification: 30 mg, Batch No.: 20211201)
[0194]
[0195] Accelerated Experiment
[0196] 30 mg of samples of Examples 1-4 were taken respectively, and impurity determination and dissolution experiments were performed at 0 day and accelerated for 1 month, 2 months, 3 months and 6 months (40°C ± 2°C, 75% ± 5% RH). The results are as follows:
[0197] Table 7 Results of capsule accelerated test (40°C ± 2°C / 75% ± 5% RH) in Example 1
[0198]
[0199] - means: data not shown or not detected
[0200] Table 8 Results of the capsule accelerated test (40°C ± 2°C / 75% ± 5% RH) of Example 2
[0201]
[0202] - means: data not shown or not detected
[0203] Table 9 Results of the capsule accelerated test (40°C ± 2°C / 75% ± 5% RH) of Example 3
[0204]
[0205] - means: data not shown or not detected
[0206] Table 10 Results of capsule accelerated test (40°C ± 2°C / 75% ± 5% RH) in Example 4
[0207]
[0208]
[0209] - means: data not shown or not detected
[0210] Long-term experiments
[0211] The sample of Example 1 was taken and subjected to impurity determination and dissolution experiments at 0 day and long-term 3 months, 6 months, 9 months and 12 months (5°C ± 3°C). The results are as follows:
[0212] Table 11 Results of long-term test of capsules in Example 1 (5°C ± 3°C)
[0213]
[0214] - means: data not shown or not detected
[0215] From the above results, it can be seen that the pharmaceutical composition of the present application has high purity and excellent stability.
[0216] Test Example 2: Bioavailability study of the composition
[0217] 1 Experimental Materials
[0218] Capsules prepared in Example 1; the raw material of the compound of formula (I) was obtained according to Preparation Example 1.
[0219] 2. Test methods
[0220] 2.1 Biological sample pretreatment
[0221] 2.1.1 Preparation of standard working solution
[0222] Standard stock solution (I-SS) of the compound of formula (I): accurately weigh 1 mg of the compound of formula (I) and place it in a 1 mL volumetric flask, add acetonitrile to dilute to the scale, sonicate to dissolve it, and prepare a stock solution with a concentration of 1 mg·mL-1.
[0223] Internal standard Tolbutamide stock solution (Tolbutamide-SS): Accurately weigh 1 mg of tolbutamide and place it in a 1 mL volumetric flask. Add acetonitrile to dilute to the scale, sonicate to dissolve it, and then prepare a stock solution with a concentration of 1 mg·mL-1.
[0224] Working solution of the standard compound of formula (I): as shown in Table 12, dilute with 50% acetonitrile to prepare a series of mixed working solutions.
[0225] Table 12 Preparation of standard working solutions of the mixed series of compounds of formula (I)
[0226]
[0227] "I-" is an abbreviation for "compound of formula (I)-".
[0228] Standard plasma samples As shown in Table 13, a series of standard plasma samples were prepared using EDTA-K2 anticoagulated beagle dog blank plasma.
[0229] Table 13 Preparation of standard plasma samples of compounds of formula (I)
[0230]
[0231] LLOQ: lower limit of quantification; QC: quality control solution; STD: standard curve; INT: transition solution; WS: working solution
[0232] 2.1.2 Preparation of internal standard (IS) solution
[0233] Take 10 μL of 1 mg·mL-1 tolbutamide reference solution, add 990 μL of acetonitrile to prepare a 10 μg·mL-1 Tolbutamide-INT solution, then take 50 μL of Tolbutamide-INT solution, add 100 mL of acetonitrile to prepare a diluted solution with a concentration of 5 ng·mL-1.
[0234] 2.2.3 Biological sample pretreatment
[0235] Take 100 μL of plasma sample, add 300 μL of tolbutamide precipitant with a concentration of 5 ng·mL-1, shake thoroughly for 3 min, centrifuge at 13000 rpm for 10 min, take 50 μL of supernatant, then add 250 μL of 50% acetonitrile solution to dilute, shake thoroughly, and inject for analysis.
[0236] 2.2 Animal Experimental Methods
[0237] 6 healthy adult male beagles were randomly divided into 2 groups. They fasted for more than 12 hours before the experiment, but were not allowed to drink water. They were fed uniformly 4 hours after the administration. Self-control was performed once, and the compound of formula (I) (raw drug capsule R) and compound of formula (I) (capsule A) were randomly cross-administered orally, with a dosage of 2 mg / dog. Before the experiment, blank blood was drawn before administration, and the drug was directly inserted into the epiglottis, so that the dog automatically swallowed and 40 mL of clean water was injected to send it down. 2 mL of forelimb venous blood was collected at 15min, 30min, 1h, 2h, 4h, 8h, 12h, and 24h, respectively, and EDTA-K2 was used for anticoagulation, placed in an ice bath, and centrifuged at 4800r·min-1 for 10min within 2 hours at 4°C to collect the upper plasma, and stored frozen at -70°C. After one week, the drugs were cross-administered in pairs. The administration cycle is as follows:
[0238] Table 14 Dosing cycle
[0239]
[0240] 3 Data processing and analysis
[0241] Data processing was automatically calculated by Analysis 1.7 software, and DAS 3.2.8 pharmacokinetic software was used to statistically analyze the pharmacokinetic parameters of the index components under various dosing conditions using a non-compartmental model.
[0242] DAS3.2.8 software was used to perform statistical calculations on the pharmacokinetic parameters. The PK parameters AUC0-t and Cmax of the test and reference preparations were logarithmically transformed. Multifactor analysis of variance (ANOVA) was used for significance testing, and then a two-way one-sided t-test was used to determine equivalence.
[0243] 4 Results
[0244] 4.1 Blood drug concentration over time after oral administration of the raw material of the compound of formula (I) in beagle dogs
[0245] After oral administration of the raw material of the compound of formula (I) to beagle dogs, the blood drug concentration data in the plasma are shown in Table 15. The drug concentration-time (CT) curve is drawn based on the drug concentration of the compound of formula (I) in the plasma after administration of the compound of formula (I). Figure 1 .
[0246] Table 15 Plasma drug concentrations (ng·mL) of the compound of formula (I) after oral administration to beagle dogs -1 ; n = 6)
[0247]
[0248]
[0249] 4.2 Blood drug concentration over time after oral administration of the compound of formula (I) capsules in beagle dogs
[0250] After oral administration of the compound of formula (I) capsule to beagle dogs, the blood drug concentration data in the plasma are shown in Table 16. The drug concentration-time (CT) curve is drawn according to the drug concentration of the compound of formula (I) in the plasma after administration of the compound of formula (I). Figure 2 .
[0251] Table 16 Plasma drug concentrations in beagle dogs after oral administration of the compound of formula (I) capsules (ng·mL-1; n=6)
[0252]
[0253] 4.3 Bioequivalence studies
[0254] 4.3.1 Pharmacokinetic parameters
[0255] The pharmacokinetic parameters of the compound preparation and raw material of formula (I) in beagle dogs are shown in the following table:
[0256] Table 17 Pharmacokinetic parameters of the preparations and raw materials of the compound of formula (I) in beagle dogs
[0257]
[0258] 5 Conclusion
[0259] The above data show that the C max The AUC to API ratio of the preparation was 1.73, and the AUC to API ratio of the preparation was 1.78. The relative bioavailability of the compound of formula (I) capsule was 177.81%.
Claims
1. A pharmaceutical composition comprising a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient, 2. The pharmaceutical composition according to claim 1, wherein The pharmaceutical composition comprises the compound represented by formula (I) or a pharmaceutically acceptable salt or a solvate thereof, and a filler, a binder, a disintegrant, a glidant or a lubricant.
3. The pharmaceutical composition according to claim 1 or 2, wherein The amount of the compound represented by formula (I) or its pharmaceutically acceptable salt or solvate is 5wt%-20wt%; or The filler is selected from one or more of starch, lactose, microcrystalline cellulose and mannitol, and the amount of the filler in the pharmaceutical composition is selected from 60wt%-90wt%; or, The binder is selected from one or more of povidone, polyethylene glycol, hydroxypropyl methylcellulose and gelatin, and the amount of the binder in the pharmaceutical composition is selected from 0.10wt%-1.00wt%; or The disintegrant is selected from one or more of dry starch, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose and cross-linked polyvinyl pyrrolidone, and the amount of the disintegrant in the pharmaceutical composition is selected from 1.00wt%-5.00wt%; or The glidant is selected from one or more of micro-powdered silica gel, talc, magnesium stearate, sodium stearyl fumarate and silicon dioxide, and the amount of the glidant in the pharmaceutical composition is selected from 0.10wt%-1.00wt%; or The lubricant is selected from one or more of micro powder silica gel, talc, hydrogenated vegetable oil, polyethylene glycol and magnesium stearate, and the amount of the lubricant in the pharmaceutical composition is selected from 0.10wt%-5.00wt%.
4. The pharmaceutical composition according to any one of claims 1 to 3, wherein Relative to the total amount of the pharmaceutical composition, the pharmaceutical composition comprises: 5wt%-20wt% of a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof; 60wt%-90wt% of a filler, wherein the filler is selected from one or more of starch, lactose, microcrystalline cellulose and mannitol, preferably selected from lactose and / or microcrystalline cellulose; 0.10wt%-1.00wt% of a binder, wherein the binder is selected from one or more of povidone, polyethylene glycol, hydroxypropyl methylcellulose and gelatin, preferably hydroxypropyl methylcellulose; 1.00wt%-5.00wt% of a disintegrant, wherein the disintegrant is selected from one or more of dry starch, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose and cross-linked polyvinyl pyrrolidone, preferably cross-linked polyvinyl pyrrolidone; 0.10wt%-1.00wt% of a glidant, wherein the glidant is selected from one or more of micro-powdered silica gel, talc, magnesium stearate, sodium stearyl fumarate and silicon dioxide, preferably silicon dioxide and / or magnesium stearate; and 0.10wt%-5.00wt% of a lubricant, wherein the lubricant is selected from one or more of micro powder silica gel, talc, hydrogenated vegetable oil, polyethylene glycol and magnesium stearate, preferably magnesium stearate.
5. The pharmaceutical composition according to any one of claims 1 to 4, comprising: (i) a granular mixture of an active agent, wherein the active agent is a compound represented by formula (I) or a pharmaceutically acceptable salt and / or a solvate thereof; and (ii) External capsule.
6. The pharmaceutical composition according to claim 5, wherein The active agent granule mixture comprises a compound represented by formula (I) or a pharmaceutically acceptable salt and / or a solvate thereof, a part of a disintegrant, a binder and a filler, The outer capsule shell contains the remainder of the disintegrant, as well as a glidant and a lubricant, Also, the granular mixture of the active agent comprises 70%-80%, preferably 72%-78%, most preferably 75% by weight of the disintegrant in the pharmaceutical composition.
7. The pharmaceutical composition according to any one of claims 1 to 6, wherein Relative to the total amount of the pharmaceutical composition, the pharmaceutical composition comprises: 5wt%-15wt% of a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof; 80wt%-90wt% of a filler, wherein the filler is selected from lactose and microcrystalline cellulose; 0.30wt%-0.50wt% of a binder, wherein the binder is hydroxypropyl methylcellulose; 2.50wt%-3.00wt% of a disintegrant, wherein the disintegrant is cross-linked polyvinylpyrrolidone; 0.60wt%-0.75wt% of a glidant, wherein the glidant is selected from silicon dioxide and / or magnesium stearate; and 0.70wt%-1.50wt% of a lubricant, wherein the lubricant is magnesium stearate.
8. The pharmaceutical composition according to any one of claims 1 to 7, wherein The pharmaceutical composition is a preparation in unit dosage form, preferably a tablet or capsule; Preferably, the unit dosage form contains 1 mg, 2 mg, 5 mg, 10 mg, 15 mg, 25 mg, or 30 mg of the compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof.
9. A method for preparing the pharmaceutical composition according to any one of claims 1 to 8, the method comprising:
1. Mixing raw materials and auxiliary materials: first, mix the filler, the compound represented by formula (I) or its pharmaceutically acceptable salt or solvate thereof for 2-10 minutes, preferably for 5 minutes, then add 60wt%-90wt%, preferably 75wt% of the disintegrant, and mix for 1-5 minutes, preferably for 3 minutes; 2. Granulation: Add 1wt%-10wt%, preferably 2wt% of an aqueous solution of a binder to the mixed raw materials to prepare a soft material, sieve through a 10-30 mesh, preferably a 20 mesh screen to granulate, and place in an oven to dry the moisture to 1wt%-3wt%; after drying, sieve through a 10-30 mesh, preferably a 18 mesh screen to size the particles; 3. Total mixing: adding the remaining amount of disintegrant, glidant and lubricant to the granules obtained in step 2, and mixing for 1-5 minutes, preferably 3 minutes, to obtain the pharmaceutical composition.
10. Use of the pharmaceutical composition according to any one of claims 1 to 8 or the pharmaceutical composition prepared by the method according to claim 9 in the preparation of a medicament for treating a disease involving ErbB kinase activity; preferably, the disease involving ErbB kinase activity is a hyperproliferative disorder, preferably cancer.
